Patterns and predictors of mortality and disease progression among patients with non‐alcoholic fatty liver disease

• DOI: 10.1111/apt.16016
• Publication Date: 2020-12-02T22:57:02Z
• Authors: Ali Canbay; Nandita Kachru; Jennifer Scarlet ...; Jan‐Peter Sowa; Dominic Meise; Ahmet Burak Ozbay
• Keywords: Steatohepatitis; Liver disease

Summary Background Factors associated with mortality and disease progression in non‐alcoholic fatty liver (NAFLD) steatohepatitis (NASH) are poorly understood. Aims To assess the impact of severity, demographics comorbidities on all‐cause a large, real‐world cohort NAFLD patients. Methods Claims data from German Institut für angewandte Gesundheitsforschung database between 2011 2016 were analyzed retrospectively. Adult patients diagnosed and/or NASH categorised as NAFLD, non‐progressors, compensated cirrhosis, decompensated transplant or hepatocellular carcinoma (HCC). The longitudinal probability incidence calculated for severity cohorts multivariable analyses performed adjusted mortality. Results Among 4 580 434 database, prevalence was 4.7% (n = 215 655). Of those, 36.8% 0.2% 9.6% 0.0005% HCC. Comorbidity rates significantly higher cirrhosis HCC compared non‐progressors. 3.6%, 18.7%, 28.8% 68%, respectively. Independent predictors included cardiovascular disease, type 2 diabetes mellitus, hypertension, obesity renal impairment. cumulative 10.7% 16.7%, respectively, over 5 years follow‐up. Conclusion severely under‐diagnosed had high that increased progression. Early identification effective management to halt reverse fibrosis essential prevent